More tools:Markets·Screener·Research·Chat

Theriva Biologics, Inc. (TOVX) Financial Statements

Theriva Biologics, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S77L07
XASE · usd
0.25▼ 0.01 (-2.33%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close0.25
Day's Range0.25 – 0.25
52-Week Range0.16 – 0.86
Volume349.9K
Avg Volume526.1K
Share Statistics
Shares Outstanding
Employees16
ExchangeXASE
Listed1993-04-05
Share count as of August 7, 2026
Loading Income Statement…
Key questions about Theriva Biologics, Inc. (TOVX)
What is Theriva Biologics, Inc.'s Market Cap?
Theriva Biologics, Inc.'s Market Cap is $11.3M, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s Enterprise Value?
Theriva Biologics, Inc.'s Enterprise Value is $1.7M, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s EV / EBITDA?
Theriva Biologics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s Net Income (TTM)?
Theriva Biologics, Inc.'s Net Income (TTM) is -$11.6M, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s EBITDA?
Theriva Biologics, Inc.'s EBITDA is -$11.8M, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s Diluted EPS (TTM)?
Theriva Biologics, Inc.'s Diluted EPS (TTM) is -0.25, based on as-reported figures from SEC (XBRL) filings.
What is Theriva Biologics, Inc.'s Net Debt?
Theriva Biologics, Inc.'s Net Debt is -$9.7M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss
License Revenue——
Operating Costs and Expenses:
General and administrative
Research and development
Total Operating Costs and Expenses
% of revenue—809.0%——
Loss from Operations
% of revenue—-709.0%——
Other Income/Expense:
Foreign currency exchange (loss) gain
Interest income
Total Other Income
Net Loss before income taxes——
Net Loss Attributable to Common Stockholders
Net Loss Per Share - Basic (in dollars per share)—
Net Loss Per Share - Dilutive (in dollars per share)—